Atropos Health

Overview
Activities
News
Telehealth?
Product stageSegments
Early
?
Asynchronous Store and Forward Service
?

Atropos Health provides its clients with insights and reports into clinical queries based on anonymized patient records. The company refers to this as their “prognostogram informatics consult”, which has a 24-hour turnaround time. The company is working on a similar consult service for oncology where treatment pathways will also be suggested based on previous patient data. Its main clients are physicians. 

In October 2023, Atropos Health launched the Geneva OS (Generative Evidence Acceleration Operating System) and ChatRWD (Real World Data) application, aimed at helping healthcare and life sciences leaders advance evidence generation. The new offering allows non-technical users to generate publication grade observational research studies using real world data from the Atropos Evidence Network. The company claimed that the new offering can expedite decision-making, generate evidence in minutes instead of weeks to months, and result in cost savings while not affecting clinical outcomes.

Key customers and partnerships

In June 2023, the company partnered with healthcare data ecosystem provider Datavant to exchange patient-level data. Through the partnership, Atropos Health users gained access to Datavant’s services, while Datavant’s ecosystem gained access to the Atropos Evidence Platform. The partnership also enabled Atropos Health to grade data present in Datavant’s ecosystem to assign a “Real World Data Score,” based on the quality of data with regard to size, completeness, longitudinality, and level of standardization and a “Real World Fitness” score, based on the data’s real-world applications. Additionally, the partnership allowed for the conversion of Datavant’s ecosystem data into real-world evidence through Atropos Health’s “Green Button Informatics Consult Service,” which creates publication-grade analytics in 48 hours.

The company also partnered with SEQESTER in December 2023 to save time, money, and accelerate drug development. Through the partnership, SEQESTER incorporated Atropos' solution to it own, allowing SEQESTER to deliver real-time and real-world data layered in AI to accelerate drug discovery.

In January 2024 the company partnered with healthcare data platform Arcadia to integrate Atropos' evidence generation capability into Arcadia's data platform, enabling value-based healthcare services and decision-making. The partnership allows Arcadia’s clients to apply Atropos’s suite of tools, which turn medical data into individual evidence supporting comprehensive patient care and performance in value-based care models. Furthermore, the collaboration will facilitate healthcare providers in creating relevant data-driven evidence to optimize care pathways and clinical guidelines and choose the best interventions for value-based care.

Also in January 2024, the company partnered with Google Cloud to accelerate real-world evidence generation for healthcare systems. Through the partnership, Atropos’ GENEVA OS platform was integrated with Google Cloud's Healthcare Data Engine (HDE) and BigQuery. This enabled company's using Atropos' services to simplify access to data, streamline analytics, and democratize insights.

Funding and financials

In May 2024, the company raised USD USD 33 million in a Series B funding round led by Valtruis, along with contributions from other venture capital firms. The company intended to use the raised funds to amplify its stake in value-based care. Specifically, it planned to fuel its work in GenAI capabilities, scaling the automation of generating personalized real-world data. Additionally, the company planned to secure partnerships with pharmaceutical and vertically integrated healthcare companies to drive evidence adoption in oncology and other specialty areas. Post funding Mike Spadafore, a value-based care veteran, joined Atropos’ board of directors.

HQ location:
Palo Alto CA USA
Founded year:
2020
Employees:
11-50
IPO status:
Private
Total funding:
USD 47.0 mn
Last Funding:
USD 33.0 mn (Series B; May 2024)
Last valuation:
-
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

EDGE Insights

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.